Filing Flows › Beta Bionics (BBNX) › Q2 2026 › vs Q2 2025
Beta Bionics (BBNX) Q2 2026 vs Q2 2025 (year over year)
Beta Bionics's revenue rose $8.8M (+38%) from $23.2M in Q2 2025 to $32.0M in Q2 2026.
Beta Bionics, Q2 2026: revenue $32.0M (+38% year over year), operating margin -79.9%, net loss $23.4M, operating cash flow −$14.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $32.0M | $23.2M | $8.8M | +38% |
| Other income, net | $2.2M | $3.0M | −$828K | -28% |
| Net loss | $23.4M | $16.9M | $6.5M | +39% |
| Costs & expenses | $57.6M | $43.1M | $14.5M | +34% |
| Operating costs | $57.6M | $43.1M | $14.5M | +34% |
| Cost of revenue | $13.1M | $10.7M | $2.4M | +22% |
| Research & development | $10.2M | $8.9M | $1.4M | +15% |
| Sales & marketing | $24.6M | $15.6M | $9.0M | +58% |
| General & admin | $9.6M | $7.9M | $1.7M | +22% |
| Operating cash sources | $23.4M | $16.9M | $6.5M | +39% |
| Depreciation | $709K | $347K | $362K | +104% |
| Share-based compensation | $7.0M | $4.8M | $2.2M | +46% |
| Working capital & other | $1.1M | −$1.9M | $2.9M | — |
| Cash used in operations | $14.6M | $13.6M | $1.0M | +8% |
| Net loss absorbed | $23.4M | $16.9M | $6.5M | +39% |
Questions
How much did Beta Bionics's revenue grow year over year in Q2 2026?
Beta Bionics's revenue rose $8.8M (+38%) from $23.2M in Q2 2025 to $32.0M in Q2 2026.